SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

SAN

83.12

+0.78%↑

MRK1

111.15

+0.14%↑

SHL.DE

46.66

-0.7%↓

ARGX

462.9

+0.65%↑

FRE

42.35

+0.14%↑

Search

Pharming Group NV

Fechado

0.889

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.88

Máximo

0.892

Indicadores-chave

By Trading Economics

Rendimento

-18M

-15M

Vendas

-14M

79M

EPS

-0.02

Margem de lucro

-18.61

Funcionários

404

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+125.11% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

18M

627M

Abertura anterior

0.89

Fecho anterior

0.889

Pharming Group NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jul. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 15:57 UTC

Conversa de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 de jul. de 2025, 15:49 UTC

Conversa de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Received All Required Authorizations

4 de jul. de 2025, 15:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Agreement Was Announced on Dec. 19

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 de jul. de 2025, 15:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 de jul. de 2025, 14:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 de jul. de 2025, 13:53 UTC

Conversa de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de jul. de 2025, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 de jul. de 2025, 12:30 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 de jul. de 2025, 12:15 UTC

Conversa de Mercado

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 de jul. de 2025, 12:13 UTC

Conversa de Mercado

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 de jul. de 2025, 12:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Pharming Group NV Previsão

Preço-alvo

By TipRanks

125.11% parte superior

Previsão para 12 meses

Média 2.004 EUR  125.11%

Máximo 2 EUR

Mínimo 2 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Pharming Group NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.